Physician profile
Mark F Pelstring
NPI 1285726232
$2,122.72
in general payments reported to CMS, 2019-2025
29 companies · $14.34 in 2025
The $14.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $242 · 2021: $1,297 · 2022: $113 · 2025: $14.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $319.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $248.27 | 2019-2021 | |
| Novo Nordisk INC | $208.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.24 | 2019-2021 | |
| Astellas Pharma US INC | $154.35 | 2019-2021 | |
| Lilly USA, LLC | $115.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $98.33 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.17 | 2020-2021 | |
| Abbvie INC. | $85.10 | 2021-2022 | |
| Glaxosmithkline, LLC. | $82.81 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $73.67 | 2019-2021 | |
| Pfizer INC. | $52.43 | 2020-2021 | |
| Hologic Sales and Service, LLC | $45.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.18 | 2019-2020 | |
| Amgen INC. | $43.46 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $37.48 | 2021 | |
| Antares Pharma, INC. | $36.12 | 2021 | |
| Boston Scientific Corporation | $25.91 | 2019-2025 | Accolade Sr |
| Sanofi-Aventis U.S. LLC | $23.74 | 2019-2021 | |
| Mylan Specialty L.P. | $22.54 | 2019 | |
| Abbott Laboratories | $18.54 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.75 | 2022 | |
| Daiichi Sankyo INC. | $17.35 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.90 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.38 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.54 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.82 | 2022 | |
| Merck Sharp & Dohme LLC | $12.43 | 2020 | |
| Allergan, INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pelstring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.